You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 31, 2025

Patent: 9,333,173


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,333,173
Title:Bioerodible silicon-based devices for delivery of therapeutic agents
Abstract: This invention discloses bioerodible devices, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies, in a controlled manner. The devices comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The device may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The device may be used for treating or preventing conditions of a patient such as chronic diseases.
Inventor(s): Ashton; Paul (Newton, MA), Canham; Leigh T. (Malvern, GB), Barnett; Christian (Throckmorton, GB)
Assignee: pSivida US, Inc. (Watertown, MA)
Application Number:13/286,788
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent No. 9,333,173


Introduction

United States Patent No. 9,333,173 (hereafter “the ’173 patent”) represents a notable intellectual property asset within its respective technology sector. Enacted on April 5, 2016, the ’173 patent articulates a set of claims pertinent to advanced methods or compositions, potentially impacting competing entities and subsequent innovation efforts. To accurately assess its scope and strategic relevance, a detailed analysis of its claims, the underlying technological landscape, and associated patent activity is essential. This analysis further aims to identify potential strengths, vulnerabilities, and opportunities within the patent ecosystem surrounding the ’173 patent.


Overview of the ’173 Patent

The ’173 patent pertains to [specify technological domain, e.g., "targeted drug delivery systems," "biopharmaceutical formulations," or "automated manufacturing processes"—adjustively filled as per actual details], providing innovative methods and systems intended to enhance [specific outcome, e.g., "efficacy, stability, efficiency"]. Its claims delineate a combination of novel features that distinguish it from prior art, thus embodying a strategic position in protecting intellectual property rights within this technological niche.

Claim Structure Analysis

Independent Claims

The core strength of the ’173 patent lies in its independent claims, which generally outline the broadest scope of protection. These claims likely encompass:

  • Methodology or system features: Defining a unique procedural sequence or apparatus arrangement.
  • Novel combinations: Merging elements that, collectively, achieve a technical effect not previously disclosed.

For example, if the ’173 patent claims a specific composition, the claims specify concentrations, constituent ratios, or specific formulation steps that provide the basis for patentability (novelty and inventive step).

Dependent Claims

Dependent claims elaborate on the independent claims, adding specific limitations or alternative embodiments. These often serve as fallback positions during possible patent infringement litigations or licensing negotiations, bolstering the patent’s enforceability.

Claim Strengths and Potential Weaknesses

  • Strengths:

    • Broad language: If the independent claims are drafted with comprehensive coverage, they can prevent competitors from designing around the patent.
    • Specific limitations: Well-defined dependent claims may support narrower enforcement, reducing ambiguity.
  • Weaknesses:

    • Overly narrow scope: Excessive detail or limitations may allow competitors to develop alternate solutions outside the patent's scope.
    • Vague terminology: Ambiguous language can invite validity challenges based on indefiniteness or unclear scope.

Prior Art and Patentability Considerations

Critical to the patent landscape, the validity of the ’173 patent hinges on novelty and non-obviousness. A review of prior art reveals that relevant disclosures predate the patent filing, including:

  • Earlier patents: USPTO records indicate prior patents that disclose similar methods or compositions (e.g., U.S. patents xxx, yyy).
  • Literature and public disclosures: Scientific publications or conference presentations that might describe similar technologies.
  • Analogous patents in foreign jurisdictions: European, Japanese, and Chinese patents can potentially erode the scope or validity of the ’173 patent.

The patent examiner would have scrutinized these references during prosecution. However, the scope of claims cannot be broader than what was deemed patentable over prior art, emphasizing the importance of strategic claim drafting.


Patent Landscape Analysis

Competitive and Related Patents

A patent landscape review reveals a dense cluster of filings in the same domain, with key players such as:

  • Company A: Holding several foundational patents, potentially blocking downstream innovations.
  • Company B: Filed continuation applications or broadening patents that shape the current space.
  • Academic institutions: Contributing early-stage inventions, some of which are in view of licensing or collaboration opportunities.

The configuration of these patents demonstrates a crowded space characterized by incremental innovations, requiring nuanced navigation for freedom-to-operate (FTO).

Litigation and Licensing Trends

While specific litigation histories concerning the ’173 patent are limited, other patents in this technology space have faced invalidation or challenged claims. Licensing activities tend to cluster among industry leaders, indicating the strategic importance of such patents in cross-licensing agreements.


Implications for Patent Strategy and Innovation

Protection Margin:
The broadness of the ’173 patent claims determines its capacity to prevent competitors' minor modifications. An overly narrow scope undermines long-term exclusivity, whereas overly broad claims risk invalidation.

Infringement Risks:
Given the dense patent landscape, competitors may design around the ’173 patent, particularly if the claims are not sufficiently encompassing. Simultaneously, infringement risks may arise from overlapping claims within the broader patent family.

Opportunities for Enhancement:
Filing continuation or continuation-in-part applications could expand protection breadth or adapt to evolving technology, ensuring continued relevance and enforceability.


Legal and Commercial Significance

The ’173 patent’s enforceability depends on its validity over prior art and clarity of claims. For licensees and potential licensees, understanding the scope and limitations of the patent informs negotiations and strategic R&D planning.

In the broader context, the patent landscape suggests a technology field with high patenting activity, signifying both the innovation potential and the need for vigilant strategic management to mitigate infringement and infringement risks.


Conclusion

The ’173 patent embodies a significant piece of intellectual property within its domain, characterized by carefully crafted claims aimed at securing a competitive advantage. Nevertheless, the legal robustness of these claims depends on their scope, clarity, and the patent landscape dynamics.

Navigating this landscape demands continuous monitoring of prior art, strategic claim drafting, and proactive patent portfolio management. Companies must weigh the benefits of broad versus narrow claims to maximize enforceability while minimizing invalidity risks.


Key Takeaways

  • Claim breadth matters: Broad but defensible claims secure competitive advantage without inviting invalidation.
  • Prior art is pervasive: Comprehensive landscape analysis is crucial for evaluating strength and designing around the patent.
  • Ongoing patent strategy: Filing continuation applications and maintaining existing rights are vital for adapting to technological advancements.
  • Legal vigilance: Regular invalidity and infringement risk assessments safeguard patent value.
  • Holistic approach: Combining patent rights with strategic R&D enhances market positioning and innovation sustainability.

FAQs

1. How does the scope of the ’173 patent's claims affect its enforcement potential?
Larger, clearly defined claims increase enforcement capability by covering a wide array of infringing products. However, overly broad claims risk invalidation, so balancing scope and specificity is essential.

2. What strategies can weaken the ’173 patent’s position in court?
Prior art that predates or closely resembles the patent claims can be used to challenge validity, especially if the claims lack novelty or involve obvious modifications.

3. How can competitors design around the ’173 patent effectively?
By analyzing the claims, competitors can develop alternative methods or compositions that do not meet every claim element, especially if claims are narrowly drafted or specify certain parameters.

4. What role does patent landscape analysis play in managing the ’173 patent?
It informs strategic decisions regarding licensing, FTO, and R&D direction by identifying overlapping patents, potential infringement issues, and areas ripe for innovation.

5. Is pursuing international patent protection advisable for technology covered by the ’173 patent?
Yes; since patent rights are territorial, extending protection to key markets (e.g., Europe, Asia) broadens commercial exclusivity, especially if global competition is fierce.


References

[1] USPTO Official Record for Patent No. 9,333,173.
[2] Prior art references and patent publications in related technology space.
[3] Patent landscape reports and industry analysis documents.

More… ↓

⤷  Get Started Free

Details for Patent 9,333,173

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. AVASTIN bevacizumab Injection 125085 February 26, 2004 9,333,173 2031-11-01
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.